Since the therapeutic targeting of this protein might provide novel strategies for the treatment of a large number of CLL patients with a disease resistant to existing drugs [37], further studies aimed at determining the exact mechanism that connects SF3B1 mutation to tumor development are warranted. This evidence concerns the gene SF3B1 and B-cell chronic lymphocytic leukemia.